The Bladder Cancer Advocacy Network (BCAN) announced the recipients of the 2017 Young Investigator Awards.
The Bladder Cancer Advocacy Network (BCAN) announced the recipients of the 2017 Young Investigator Awards. The Young Investigator Awards support the development of outstanding research scientists and clinical cancer research investigators who have demonstrated a commitment to improving the understanding and treatment of bladder cancer. BCAN is pleased to grant two awards of $50,000 to support one year of research.
The Stephen Hale Gushée Young Investigator Award will support the research of Tracy Rose, MD, MPH, Assistant Professor at UNC Chapel Hill, for her research, “Defining the Immune Response to Chemotherapy and Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer.” While newly approved immunotherapy treatments are showing great promise for many bladder cancer patients, the complicated immune system changes seen with standard chemotherapy and chemotherapy in combination with immunotherapy have not been studied in bladder cancer. Dr. Rose’s work will assist the development and optimization of chemo-immunotherapy combinations in bladder cancer to ultimately improve the cure rate of this deadly disease.
The JPB Foundation Young Investigator Award will further the research of Byron Lee, MD, PhD, Assistant Professor at the Cleveland Clinic Foundation, on “Ascertaining the Role of Mutations in COMPASS- like Complex Members in the Development of Upper Tract Urothelial Carcinoma.” Upper tract urothelial carcinoma (UTUC) accounts for 5-10% of all urothelial carcinomas, and very few treatment options exist, especially for those patients who have disease recurrence after kidney removal and inadequate kidney function for cisplatin-based chemotherapy. Dr. Lee will be investigating how mutations affect disease progression and response to therapy, with the goal of deepening the understanding of how UTUC arises and also to provide novel drug targets for testing.
“Since we began our Young Investigator Awards, BCAN has invested more than one million dollars to support early career investigators like Dr. Rose and Dr. Lee. Advancing quality research has always been a top priority for BCAN. Funding their work exemplifies our efforts to make a difference in the lives of those diagnosed with bladder cancer. We are grateful for the generous support from The JPB Foundation and the family and friends of Stephen Hale Gushée for making these awards possible,” stated Andrea Maddox-Smith, Chief Executive Officer of BCAN.
For more information about BCAN go to www.bcan.org or call 1-888-901-BCAN (2226).
Key Advances in Cancer Survivorship Toxicity Management
July 15th 2022In this episode of The Vitals, Lidia Schapira, MD, FASCO, recounts highlights from the 2022 ASCO Symptoms and Survivorship track and underscores key takeaways for practitioners seeking to enhance the delivery of cancer survivorship care.
Maintenance Avelumab Has Similar Efficacy in Real World for Urothelial Cancer
March 5th 2024Patients with metastatic urothelial cancer treated with frontline maintenance therapy with avelumab following platinum-based chemotherapy in the real-world setting had similar outcomes as observed in the JAVELIN Bladder 100 trial.